Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2021-05-06 , DOI: 10.1002/cti2.1282
Aiko Hasegawa ₁ , Shoji Saito _{1,

2} , Shogo Narimatsu _{3,

4} , Shigeru Nakano _{3,

4} , Mika Nagai ₁ , Hideki Ohnota ₃ , Yoichi Inada _{1,

3} , Hirokazu Morokawa ₁ , Ikumi Nakashima ₁ , Daisuke Morita _{1,

5} , Yuichiro Ide ₆ , Kazuyuki Matsuda ₇ , Haruko Tashiro ₈ , Shigeki Yagyu _{2,

9} , Miyuki Tanaka _{1,

2} , Yozo Nakazawa _{1,

2,

5}

Affiliation

As the prognosis of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains poor, novel treatment strategies are urgently needed. Clinical trials have shown that chimeric antigen receptor (CAR)‐T cells for AML are more challenging than those targeting CD19 in B‐cell malignancies. We recently developed piggyBac‐modified ligand‐based CAR‐T cells that target CD116/CD131 complexes, also known as the GM‐CSF receptor (GMR), for the treatment of juvenile myelomonocytic leukaemia. This study therefore aimed to develop a novel therapeutic method for R/R AML using GMR CAR‐T cells.

中文翻译：

突变的基于 GM-CSF 的 CAR-T 细胞靶向 CD116/CD131 复合物对急性髓细胞白血病表现出增强的抗肿瘤作用

由于复发/难治性 (R/R) 急性髓性白血病 (AML) 的预后仍然很差，迫切需要新的治疗策略。临床试验表明，用于 AML 的嵌合抗原受体 (CAR)-T 细胞比靶向 CD19 的 B 细胞恶性肿瘤更具挑战性。我们最近开发了piggyBac修饰的基于配体的 CAR-T 细胞，该细胞靶向 CD116/CD131 复合物，也称为 GM-CSF 受体 (GMR)，用于治疗幼年型骨髓单核细胞白血病。因此，本研究旨在开发一种使用 GMR CAR-T 细胞治疗 R/R AML 的新方法。

更新日期：2021-05-07

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文